U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241793) titled 'Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)' on Sept. 24.
Brief Summary: This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC).
Study Start Date: Nov. 20
Study Type: INTERVENTIONAL
Condition:
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Urothelial Carcinoma Recurrent
Intervention:
DRUG: Adebrelimab
Adebrelimab...